CoagulationDisorders near Englewood, NJ

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Andrew H. Lipsky is an Assistant Professor of Medicine at the Columbia University Medical Center. He specializes in caring for adult patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and lymphoma.Dr. Lipsky's research focuses on cancer genomics and new treatments for CLL. He has a special interest in using the latest bioinformatics techniques to study how cancer cells change and adapt during treatment. Utilizing these genomic insights, he hopes to better inform clinical trials and hasten the development of innovative therapies for patients with hematologic malignancies.Dr. Lipsky earned his medical degree from Rutgers - Robert Wood Johnson Medical School. He completed internship and residency in internal medicine at Montefiore - Albert Einstein College of Medicine. He completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital Weill Cornell Medical College, with an additional sub-fellowship in the clinical care of CLL and lymphoma. He also completed a postdoctoral research fellowship in lymphoma genomics and bioinformatics as part of the Molecular and Translation Oncology Research (MTOR) training program.

Biography: Dr. Hua-Jay "Jeff" Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. His research on ctDNA in patients with relapsed lymphoma receiving chimeric antigen receptor T-cell therapy is funded by a Conquer Cancer Young Investigator Award grant. He is a member of Southwestern Oncology Group Lymphoma Working Group and Committee. He was selected to participate in the Academy of Next Wave of Investigators for non-Hodgkin's lymphoma and the American Society of Hematology Clinical Research Training Institute, competitive programs aimed at supporting academic and career development for promising clinical researchers. Dr. Cherng's goal is to design clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.

Biography: Pawel Muranski, MD, trained as a Hematologist and Oncologist at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH) in Bethesda, Maryland where he subsequently worked as a faculty in the Stem Cell Allogeneic Transplantation Section. He joined Columbia University in 2017 as the Director of Cellular Immunotherapy. Dr. Muranski specializes in bone marrow transplant (BMT).

Biography: Manuela Orjuela-Grimm is a molecular epidemiologist and pediatric oncologist whose research focuses on vulnerability (including social) to environmental exposures, gene-nutrient/ environment interactions during windows of susceptibility such as pregnancy, early childhood, adolescence and the development of later genetic and epigenetic changes contributing to poorer health outcomes in childhood and adolescence. She leads EpiRbMx, a long-standing case control/ case series study examining exposure to methyl donors, folate pathway metabolism and risk for retinoblastoma in collaboration with a multidisciplinary team of investigators including the Hospital Infantil de Mexico, the Hospital de Pediatria at the Instituto Mexicano de Seguro Social (IMSS), the Instituto Nacional de Salud Publica (INSP), and the University of Toronto. In collaboration with INSP researchers, Dr. Orjuela is involved in multiple studies examining the intersection between food security, folate-related dietary intake, dietary diversity and environmental exposures in central Mexico, and in immigrants in New York. Interests: social contributors to dietary exposures, gene-nutrient interactions; one carbon donor metabolism; methylation; nutrient and environmental exposures during early life and later genetic and epigenetic effects; dietary assessment in Mexico, in populations on the move in Latin America; effects of acculturation and early life migration on nutrient/ environmental exposures in US Latinos.

Biography: Originally from Columbus, OH, SunilIyercompleted his undergraduate studies at Washington University in St. Louis. He then completed his medical education and training at the University of Miami, where he served as chief hematology/oncology fellow. He has a strong interest in leukemia, particularly in the genomics and treatment of acute lymphoblastic leukemia.